Azmasol Plus120 Metered Inhalations

Primary Indication

Azmasol Plus 120 Metered Inhalations inhalation therapy is indicated for the management of asthma in adult patients.

Therapeutic Uses

• Treatment of Asthma (Adults 18 Years and Older):
  Used for the regular management and control of asthma symptoms in patients aged 18 years and above.
• Prevention of Bronchoconstriction:
  Helps prevent narrowing of the airways, thereby improving breathing and reducing episodes of wheezing, shortness of breath, and chest tightness.
• Reduction of Asthma Exacerbations:
  Helps decrease the risk and frequency of asthma flare-ups in patients with persistent asthma.

Clinical Role

This combination therapy works by:

• Salbutamol: Providing rapid bronchodilation to relieve airway constriction
• Budesonide: Reducing airway inflammation and improving long-term asthma control

Together, they provide both quick symptom relief and long-term disease control.

Summary

Azmasol Plus 120 Metered Inhalations inhalation therapy is indicated for the treatment and maintenance of asthma in adults (≥18 years), including prevention of bronchoconstriction and reduction of asthma exacerbations through combined bronchodilator and anti-inflammatory action.

Pharmacological Class

Azmasol Plus 120 Metered Inhalations is a fixed-dose combination inhalation therapy that includes:

• Salbutamol: A selective β2-adrenergic receptor agonist
• Budesonide: A potent inhaled corticosteroid (ICS)

This combination is used for the as-needed relief and prevention of bronchoconstriction and for reducing the risk of asthma exacerbations in adults aged 18 years and older.

Mechanism of Action

Salbutamol (Bronchodilator Action)

• Stimulates β2-adrenergic receptors in bronchial smooth muscle.
• Leads to relaxation of airway smooth muscles from the trachea to the terminal bronchioles.
• Produces rapid bronchodilation, resulting in quick relief of bronchospasm and improved airflow.

Budesonide (Anti-inflammatory Action)

• Exhibits strong glucocorticoid activity in the airways.
• Suppresses multiple inflammatory cells and mediators involved in asthma pathophysiology, including:
  • Eosinophils
  • Mast cells
  • Cytokines and inflammatory enzymes
• Reduces airway inflammation, hyperresponsiveness, and mucus production.

Combined Therapeutic Effect

• Salbutamol provides rapid symptom relief by opening constricted airways.
• Budesonide provides long-term control by reducing underlying airway inflammation.

Together, they offer both fast bronchodilation and sustained anti-inflammatory control, improving overall asthma management and reducing the risk of exacerbations.

Summary

Azmasol Plus 120 Metered Inhalations is a dual-action inhaled therapy combining a rapid-acting β2-agonist and an inhaled corticosteroid to provide quick relief of bronchoconstriction and long-term reduction of airway inflammation in adult asthma patients.

CYP3A4 Inhibitors

• Strong CYP3A4 inhibitors (e.g., ritonavir and other similar agents) may increase systemic exposure to budesonide.
• This can lead to an increased risk of systemic corticosteroid effects, such as adrenal suppression or corticosteroid-related adverse reactions.

Beta-Blockers

• Non-selective beta-blockers may reduce the bronchodilator effect of salbutamol.
• They may also induce severe bronchospasm in patients with asthma, and therefore should generally be avoided unless clearly indicated.

Diuretics

• Use with non–potassium-sparing diuretics may enhance the risk of hypokalemia (low potassium levels).
• This may also increase the likelihood of electrocardiographic (ECG) changes, especially in susceptible patients.

Digoxin

• Salbutamol may reduce serum digoxin levels, potentially decreasing its therapeutic effect.
• Monitoring of digoxin levels may be required when used concurrently.

Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants

• Concomitant use with MAO inhibitors or tricyclic antidepressants should be done with extreme caution.
• These combinations may potentiate cardiovascular effects of beta-agonists, such as increased heart rate or blood pressure changes.

Summary

Azmasol Plus 120 Metered Inhalations inhalation therapy has clinically significant interactions with CYP3A4 inhibitors, beta-blockers, diuretics, digoxin, and certain antidepressants. Careful monitoring and medical supervision are essential when used alongside these medications.

Azmasol Plus 120 Metered Inhalations inhalation therapy may cause a range of adverse effects, varying in severity and frequency. These effects are generally related to either the bronchodilator (salbutamol) or corticosteroid (budesonide) components.

Respiratory System Effects

• Worsening of Asthma:
  In some cases, asthma symptoms may paradoxically worsen after inhalation.
• Paradoxical Bronchospasm:
  Rare but serious narrowing of the airways immediately after use, requiring discontinuation of therapy.

Cardiovascular Effects

• Palpitations
• Tachycardia (increased heart rate)
• ECG changes in susceptible individuals
  These effects are mainly associated with the salbutamol component.

Hypersensitivity Reactions

• Rash, itching, or urticaria
• Rare cases of anaphylactic reactions
• Angioedema (swelling of face, lips, or throat)

Metabolic and Electrolyte Disturbances

• Hypokalemia (low potassium levels)
  May occur, especially with high or frequent dosing.

Corticosteroid-Related Effects (Budesonide)

• Oral or oropharyngeal candidiasis (thrush)
• Immunosuppression, increasing susceptibility to infections
• Hypercorticism and adrenal suppression (with prolonged or excessive use)
• Reduced bone mineral density with long-term therapy
• Glaucoma and cataracts (with extended use)

Endocrine and Growth Effects

• Potential growth suppression in pediatric patients with long-term corticosteroid exposure

Summary

Azmasol Plus 120 Metered Inhalations inhalation therapy is generally effective and well tolerated, but may cause respiratory, cardiovascular, metabolic, and corticosteroid-related adverse effects. Serious reactions such as paradoxical bronchospasm and systemic corticosteroid effects require prompt medical attention.

Pregnancy

There are no adequate and well-controlled clinical studies in pregnant women using this combination inhaler to clearly establish a drug-related risk. However, available evidence provides some reassuring data:

• Salbutamol:
  Epidemiological studies and post-marketing reports of inhaled salbutamol use during pregnancy do not consistently show an increased risk of major birth defects or miscarriage.
• Budesonide:
  Clinical reviews of inhaled budesonide use in pregnant women have not demonstrated a significant association with:
  • Major congenital malformations
  • Miscarriage
  • Other adverse maternal or fetal outcomes

Clinical Considerations in Pregnancy

• Asthma control during pregnancy is important for both maternal and fetal health.
• Treatment decisions should balance the potential risks of medication exposure against the risks of uncontrolled asthma.

Lactation (Breastfeeding)

• There are currently no sufficient data on the effects of this combination inhaler on:
  • Breastfed infants
  • Human milk production
• The potential risk to the breastfed child cannot be fully ruled out.

Clinical Considerations in Lactation

• Use during breastfeeding should be considered only if the expected benefits justify the potential risks.
• Monitoring of the infant may be advised in cases of prolonged maternal use.

Summary

Azmasol Plus 120 Metered Inhalations inhalation therapy does not show clear evidence of major pregnancy-related risks based on available data for its individual components, but controlled studies are limited. Safety data during lactation are insufficient, so cautious use under medical supervision is recommended.

Asthma Deterioration and Disease Monitoring

• Asthma symptoms may worsen acutely (within hours) or progressively over days.

• If patients require increased use of this inhaler or experience persistent symptoms, it may indicate loss of asthma control.

• Such cases require prompt clinical reassessment of the patient and their treatment regimen.

Paradoxical Bronchospasm

• This inhaler may cause paradoxical bronchospasm, which can be life-threatening.

• If it occurs, the medication should be discontinued immediately, and alternative therapy initiated.

Cardiovascular Effects

• Like other β2-agonists, salbutamol may cause clinically significant cardiovascular effects, including:

  • Increased heart rate (tachycardia)

  • Elevated blood pressure

• Excessive use may lead to serious cardiovascular events, including rare fatal outcomes.

• Patients developing these effects may require discontinuation of therapy.

Hypersensitivity Reactions

• Severe allergic reactions may occur, including:

  • Anaphylaxis

  • Angioedema

  • Bronchospasm

  • Rash and urticaria

• Treatment should be discontinued immediately if hypersensitivity occurs.

Electrolyte Imbalance

• β-adrenergic agonists may cause hypokalemia, which can contribute to cardiovascular complications in susceptible patients.

Immunosuppression and Infection Risk

• Patients receiving corticosteroids may have increased susceptibility to infections.

• Conditions such as chickenpox and measles may be more severe or even fatal in susceptible individuals.

• Exposure should be avoided in non-immune patients.

Local and Systemic Corticosteroid Effects (Budesonide)

• Oropharyngeal candidiasis (thrush) may occur; patients should be monitored regularly.

• Long-term use may be associated with:

  • Reduced hypothalamic-pituitary-adrenal (HPA) axis function (less than oral steroids but still possible)

  • Decreased bone mineral density (BMD)

  • Increased risk of osteoporosis in predisposed individuals

• Risk factors include advanced age, poor nutrition, immobilization, post-menopausal status, smoking, and long-term corticosteroid use.

Ocular Effects

• Long-term inhaled corticosteroid use may lead to:

  • Glaucoma

  • Increased intraocular pressure

  • Cataracts

Drug Interactions (CYP3A4 Inhibitors)

• Caution is required when used with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, itraconazole, clarithromycin).

• These drugs may increase systemic exposure to budesonide, increasing the risk of corticosteroid-related adverse effects.

Pediatric Considerations

• Inhaled corticosteroids may reduce growth velocity in children.

• Safety and efficacy have not been established in pediatric patients; therefore, this inhaler is not indicated for use in children.

Special Precautions

• Use cautiously in patients with:

  • Convulsive disorders

  • Hyperthyroidism

  • Diabetes mellitus

  • Increased sensitivity to sympathomimetic amines

Summary

Azmasol Plus 120 Metered Inhalations inhalation therapy requires careful monitoring due to risks of asthma worsening, cardiovascular effects, bronchospasm, electrolyte imbalance, infection susceptibility, and long-term corticosteroid complications. Immediate discontinuation is required in cases of severe hypersensitivity or paradoxical bronchospasm.

General Consideration

This inhaler contains both salbutamol and budesonide; therefore, overdose effects may reflect toxicity from either or both components. The clinical effects depend on the amount and duration of excessive use.

Salbutamol Overdose Effects

Excessive intake of salbutamol may lead to intense β2-adrenergic stimulation, resulting in a wide range of systemic effects, including:

• Cardiovascular Effects:

  • Tachycardia (may reach up to 200 beats/minute)

  • Arrhythmias

  • Angina

  • Blood pressure changes (hypertension or hypotension)

  • Palpitations

• Central Nervous System Effects:

  • Nervousness and agitation

  • Tremor

  • Headache

  • Dizziness

  • Insomnia

• Metabolic Effects:

  • Hyperglycemia

  • Metabolic acidosis

  • Hypokalemia

• Other Symptoms:

  • Muscle cramps

  • Dry mouth

  • Nausea

  • Fatigue and malaise

  • Seizures (in severe cases)

Budesonide Overdose Effects

Excessive or prolonged use of budesonide may result in systemic corticosteroid effects, including:

• Hypercorticism (Cushingoid features)

• Suppression of normal adrenal function (HPA axis suppression)

• Other corticosteroid-related systemic effects with long-term high-dose exposure

Clinical Management

• Treatment is primarily supportive and symptomatic.

• Monitoring of:

  • Cardiovascular status

  • Electrolyte balance (especially potassium levels)

  • Blood glucose levels

• Medical supervision is required in all suspected overdose cases.

Summary

Overdose of Azmasol Plus 120 Metered Inhalations inhaler may cause significant β-agonist toxicity (cardiac, metabolic, and neurological effects) from salbutamol and systemic corticosteroid effects from budesonide, particularly with prolonged excessive use. Management is supportive with close clinical monitoring.

General Storage Requirements

• Store the inhaler at a temperature not exceeding 30°C.
• Keep in a cool, dry place away from moisture.
• Protect from direct sunlight and heat exposure.
• Keep the medication out of reach of children.
• Avoid contact with eyes.

Pressurized Container Safety

• The inhaler contains a pressurized canister.
• Do not puncture, break, or incinerate the canister, even when empty, as it may explode under heat or pressure.

Handling and Maintenance

• Clean the inhaler regularly according to provided instructions.
• Shake well before each use for proper dose delivery.
• For best results, ensure the canister is at room temperature before use.

Shelf-Life and Usage After Opening

• Use the inhaler within 6 months after removing it from the foil pouch.

Summary

Azmasol Plus 120 Metered Inhalations inhaler should be stored in a cool, dry environment below 30°C, protected from heat, sunlight, and damage. Proper handling, timely use after opening, and safe storage of the pressurized canister are essential for maintaining effectiveness and safety.